As Founder and Principal Consultant at Ridgewell Consulting, LLC, Dr. Ridgewell is responsible for guiding clients with strategic direction and development plan execution for the nonclinical aspects of drug development programs. He provides consultation focused on scientific and regulatory aspects of nonclinical drug development across the disciplines of pharmacology, toxicology and drug metabolism and pharmacokinetics. Dr. Ridgewell’s expertise includes the integration of nonclinical findings toward prediction of human dose and exposure, efficacy, and safety toward successful regulatory submissions. Before establishing Ridgewell Consulting, he held positions of increasing responsibility and influence over more than 28 years in Drug Discovery and Drug Development within the pharmaceutical industry in North America, including Upsher-Smith, Boehringer-Ingelheim, Pharmacia (Pfizer), 3M Pharmaceuticals and Bristol-Myers Squibb. Dr. Ridgewell also gained direct contract research experience as a Research Director at Covance Laboratories. He has presented on twelve drug discovery and development topics at scientific conferences, participated as an instructor in continuing education courses for pharmaceutical scientists, authored nine peer-reviewed publications, and co-authored a book chapter on drug-transporter interactions. Dr. Ridgewell holds a Bachelor’s degree in Chemistry and a Ph.D. in Medicinal Chemistry from the University of Minnesota.